Cargando…
Use of Erythropoiesis-Stimulating Agents Among Chemotherapy Patients With Hemoglobin Exceeding 12 Grams Per Deciliter
BACKGROUND: Prior to 2007, the erythropoiesis-stimulating agents (ESAs) epoetin alfa and darbepoetin alfa were indicated for use in chemotherapy induced anemia to achieve target hemoglobin (Hb) levels of approximately 12 grams per deciliter (gm per dL), and treatment was to be withheld if Hb exceede...
Autores principales: | Nordstrom, Beth L., Luo, Weixiu, Fraeman, Kathy H., Whyte, Joanna L., Nordyke, Robert J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Academy of Managed Care Pharmacy
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438319/ https://www.ncbi.nlm.nih.gov/pubmed/19006442 http://dx.doi.org/10.18553/jmcp.2008.14.9.858 |
Ejemplares similares
-
No TREATment with Darbepoetin Dosed to Hemoglobin 13 Grams per Deciliter in Type 2 Diabetes with Pre-Dialysis Chronic Kidney Disease - Safety Warnings for Erythropoiesis-Stimulating Agents
por: Curtiss, Frederic R.
Publicado: (2009) -
Incidence of New-Onset Hypertension in Cancer Patients: A Retrospective Cohort Study
por: Fraeman, Kathy H., et al.
Publicado: (2013) -
Hemoglobin decline in cancer patients receiving chemotherapy without an erythropoiesis-stimulating agent
por: Pirker, Robert, et al.
Publicado: (2012) -
Mechanisms of hemoglobin cycling in anemia patients treated with erythropoiesis-stimulating agents
por: Jörg, David J., et al.
Publicado: (2023) -
Implications of a Reduction in the Hemoglobin Target in Erythropoiesis-Stimulating Agent-Treated Hemodialysis Patients
por: Nguyen, Timothy V., et al.
Publicado: (2011)